Clinical trials: Cutaneous Lupus
Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed…
- Trial name
- NCT06875960
- Testing
- BMS-986165
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Research Accelerated by You Lupus Registry
Summary The Lupus Foundation of America (LFA) Research Accelerated by You (RAY) Registry is a fully remote, longitudinal registry designed to collect data from adults and children living with lupus.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Cutaneous Lupus Erythematosus (CLE)
- Trial name
- RAY (NCT06927219)
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Lupus Foundation of America
Cutaneous Lupus Erythematosus (CLE)
Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)
This study is being conducted to evaluate the safety and effectiveness of lenalidomide (Revlimid®) in subjects with Cutaneous Lupus Erythematosus (CLE).
- Trial name
- NCT00633945
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
Discoid Lupus Erythematosus (DLE)
The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus
A 20 week study to assess the safety and efficacy of etanercept(Enbrel®)for the treatment of Discoid Lupus Erythematosus
- Trial name
- DISCLUP2008 (NCT00797784)
- Testing
- etanercept(Enbrel®)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Florida Academic Dermatology Centers
Lupus Erythematosus, Cutaneous
Efficacy of Fractional Er:YAG Laser in Lupus Erythematosus Scars
Cutaneous Lupus erythematosus (CLE) is a chronic autoimmune connective tissue disease with a prevalence of 14.6 - 73.2/100,000, predominantly in women in mid adulthood.
- Trial name
- NCT04707924
- Testing
- Er:YAG laser
- Where
- Switzerland
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases.
- Conditions
- Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
- Trial name
- CARTIMMUNE (NCT06152172)
- Testing
- KYV-101, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- David Porter
Discoid Lupus Erythematosus
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
This study is a single-blind, intraindividual study to evaluate the efficacy of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus.
- Trial name
- NCT06261021
- Testing
- Ruxolitinib 1.5% cream, Application without occlusion in Area 1, Application under occlusion at night in Area 2
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Innovaderm Research Inc.
Cutaneous Lupus Erythematosus
Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus
Lupus is a disease in which the immune system, which normally fights infection, begins to attack healthy cells in the body. This phenomenon is called autoimmunity and what the immune system attacks is called the autoantigen.
- Trial name
- NCT01498406
- Testing
- vitamin D
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Emory University
Lupus Erythematosus, Discoid, Lupus Erythematosus, Cutaneous
Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus
The purpose of this study is to determine whether Etanercept which is given through intradermal injection is effective in the treatment of discoid lupus erythematosus (DLE).
- Conditions
- Lupus Erythematosus, Discoid, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Chronic Cutaneous
- Trial name
- TARGET-DLE (NCT02656082)
- Testing
- Etanercept
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- University of Leeds
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic…
- Trial name
- ELOWEN-1 (NCT07332481)
- Testing
- Enpatoran, Standard of care (SoC)
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 202 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Discoid Lupus Erythematosus
Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus
A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with moderate-to-severe active primary Discoid Lupus Erythematosus (DLE) refractory to…
- Trial name
- NCT05591222
- Testing
- Daxdilimab
- Where
- 68 sites in United States, Argentina and 9 more
- Volunteers
- 72 people
- Sponsor
- Amgen
Lupus Erythematosus, Cutaneous
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects
This study is designed to examine safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effect of repeat dosing of GSK2646264 in patients with subacute and chronic cutaneous lupus erythematosus (CLE) lesions and…
- Trial name
- NCT02927457
- Testing
- GSK2646264 1%
- Where
- 5 sites in Germany
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Healthy Volunteers, Systemic Lupus Erythematosus (SLE)
A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus
Part 1 : To evaluate the safety and tolerability of a single intravenous (IV) or subcutaneous (SC) dose of KK4277 in healthy Japanese or non-Asian adult males.
- Conditions
- Healthy Volunteers, Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
- Trial name
- NCT05411016
- Testing
- KK4277
- Where
- 23 sites in Japan, South Korea
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Cutaneous Lupus Erythematosus
Low-dose UVA1 Radiation in Cutaneous Lupus Patients
The investigators are conducting an open-label clinical trial determining the effects of UVA1 phototherapy on cutaneous lupus (CLE) patients.
- Trial name
- NCT01776190
- Testing
- UVA1 radiation treatment
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ben Chong
Discoid Lupus Erythematosus
A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
Discoid lupus erythematosus is a chronic inflammatory skin condition and may lead to itch, skin pain, open sores, scarring, disfigurement and hair loss.
- Trial name
- NCT03866317
- Testing
- Secukinumab
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Discoid Lupus Erthematosus of the Scalp
Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva
The purpose of this study is to investigate the efficacy of Raptiva (efalizumab) in the treatment of discoid lupus erythematosus (DLE).
- Trial name
- NCT00308204
- Testing
- Raptiva
- Where
- United States
- Sponsor
- The Cleveland Clinic
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Study of M5049 in CLE and SLE Participants
This study is to evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered M5049 in participants with systemic lupus erythematosus (SLE) or cutaneous lupus erythematosus (CLE).
- Trial name
- NCT04647708
- Testing
- M5049
- Where
- 12 sites in Bulgaria, Germany and 4 more
- Volunteers
- 25 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Cutaneous Lupus Erythematosus (CLE)
Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus
Cutaneous lupus erythematosus (CLE) is a heterogeneous inflammatory autoimmune disease associated or not with systemic lupus erythematosus (SLE).
- Trial name
- LEISURE (NCT06965244)
- Testing
- Lenalidomide, Methotrexate (MTX)
- Volunteers
- 122 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid
Autologous Polyclonal Tregs for Lupus
The primary purpose of this Phase 1 study is to evaluate the safety, tolerability, and effect of 3 different doses of Treg therapy in adults with skin (cutaneous) involvement of their lupus.
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
- Trial name
- NCT02428309
- Testing
- Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus.
- Trial name
- NCT06980805
- Testing
- IMVT-1402
- Where
- 86 sites in United States, Argentina and 11 more
- Volunteers
- 56 people
- Sponsor
- Immunovant Sciences GmbH